This filing removes a key operational risk for Kyverna's commercial launch by locking in manufacturing capacity, but provides no new financial data or catalyst. The next major event is the completion of the rolling BLA submission for miv-cel in SPS, expected in Q4 2026. Monitor for FDA acceptance and any pricing details in the upcoming 10-Q.
Price Chart
Executive Summary
Kyverna Therapeutics entered into a 5-year Clinical and Commercial Supply Agreement with ElevateBio for its lead CAR T-cell therapy, miv-cel, replacing the prior clinical-stage agreement. The deal secures manufacturing capacity for the upcoming U.S. commercial launch in stiff person syndrome (SPS), where a rolling BLA submission is on track for Q4 2026. This is a routine operational milestone for a pre-commercial biotech, removing manufacturing overhang but providing no financial data or fundamental business change.
Key Facts
- Kyverna and ElevateBio entered a Clinical and Commercial Supply Agreement for miv-cel, replacing the prior clinical-stage agreement.
- The agreement has a 5-year initial term with automatic one-year renewals and includes minimum purchase commitments post-approval.
- Kyverna is on track to complete its rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026.
- ElevateBio achieved a clinical manufacturing success rate of more than 98% for miv-cel.
- No financial terms (upfront payments, pricing, minimum quantities) were disclosed in the filing.
Financial Impact
No financial terms disclosed; the agreement replaces a prior clinical-stage contract and includes minimum purchase commitments post-approval, but no upfront or milestone payments were reported.
Risk Factors
- No financial terms disclosed — the agreement's cost structure and minimum commitments remain unknown.
- Kyverna is pre-revenue and dependent on FDA approval of miv-cel; any regulatory delays would render this agreement a liability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-316916 |
| Document: kytx-ex99_1.htm | 0001193125-26-316916 |
| Document: 0001193125-26-316916-index-headers.html | 0001193125-26-316916 |
| Document: 0001193125-26-316916-index.html | 0001193125-26-316916 |
| Document: 0001193125-26-316916.txt | 0001193125-26-316916 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers